NasdaqGS:ZBIOBiotechs
Why Zenas BioPharma (ZBIO) Is Up 20.6% After Index Inclusion And ESOP Shelf Filing – And What's Next
In December 2025, Zenas BioPharma was added to the NASDAQ Biotechnology Index and filed a US$45.59 million shelf registration tied to an employee stock ownership plan, as investors focused on upcoming Phase 3 INDIGO trial results for its lead drug obexelimab in IgG4-Related Disease.
The convergence of index inclusion, fresh capital flexibility, and obexelimab’s pivotal data approaching has put Zenas at the center of growing analyst and investor attention around IgG4-RD therapeutics.
Against...